Clinical Trials Logo

Myeloproliferative Neoplasms clinical trials

View clinical trials related to Myeloproliferative Neoplasms.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04866056 Terminated - Clinical trials for Myelodysplastic Syndromes

Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF.

Start date: September 30, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies how well Jaktinib and azacytidine work in treating patients with myelodysplastic syndromes with myelofibrosis or myelodysplastic syndrome/myeloproliferative neoplasm with myelofibrosis. Giving Jaktinib and azacytidine may be an effective treatment for myelodysplastic syndromes with myelofibrosis or myelodysplastic syndrome/myeloproliferative neoplasm with myelofibrosis.

NCT ID: NCT02393248 Terminated - Breast Cancer Clinical Trials

Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)

Start date: February 27, 2015
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study will be to evaluate the safety, tolerability, and pharmacological activity of pemigatinib in subjects with advanced malignancies. This study will have three parts, dose escalation (Part 1), dose expansion (Part 2) and combination therapy (Part 3).

NCT ID: NCT01668173 Terminated - Clinical trials for Myeloproliferative Neoplasms

HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET

Start date: August 2012
Phase: Phase 2
Study type: Interventional

The purpose of this study is to test a new drug called AUY922. AUY922 is not FDA-approved. AUY922 is a new kind of drug that attacks a protein called HSP90. HSP90 is found in both normal and cancer cells, but the investigators think it is more important in cancer cells. This study will see if AUY922 helps people with myelofibrosis, essential thrombocythemia and polycythemia vera. This study will also see if AUY922 is safe in people with myelofibrosis, essential thrombocythemia and polycythemia vera. It will find out what effects, good and/or bad, AUY922 has on the patient and the disease. The researchers hope that this study will help them to find better treatments for primary myelofibrosis, essential thrombocythemia and polycythemia vera.